Clik here to view.
Bayer's treatment for menopause symptoms hits primary endpoints in third...
Bayer touted more detailed data from a Phase 3 trial for elinzanetant, a non-hormonal drug candidate that it’s investigating as a treatment for menopause symptoms like hot flashes and night sweats. The...
View ArticleClik here to view.
Roivant unveils its next deal, hoping for TL1A-sized potential from a shelved...
Nearly a year after agreeing to a $7 billion-plus sale for an inflammatory bowel disease drug candidate, Roivant Sciences is pitching big potential in another drug from the back of a drugmaker’s...
View ArticleExclusive: Bain scoops up $3B for fourth life sciences fund after handful of...
Bain Capital Life Sciences has reeled in about $3 billion for its fourth fund, Endpoints News has learned. The Boston-based firm has been on a spree in recent quarters. Its portfolio companies Aiolos...
View ArticleCentessa to take narcolepsy drug into Phase 2 after no sign of side effects...
Centessa Pharmaceuticals plans to take its orexin receptor 2 agonist into mid-stage testing for narcolepsy after a Phase 1 study showed signs of efficacy. The drug, ORX750, was tested in sleep-deprived...
View ArticleUpdated: Viridian reveals first Phase 3 eye disease data in bid to compete...
Viridian Therapeutics on Tuesday reported topline Phase 3 data for its rare autoimmune disease drug veligrotug as it aims to compete with Amgen and Horizon’s Tepezza. Veligrotug hit on all primary and...
View ArticleIonis’ $500M offering; Terns aims to raise $125M
Plus, news about Chai Discovery, Relay Therapeutics, Incannex Healthcare, PhoreMost, Epsilogen and LIFTT: Ionis prices $500M offering: The veteran RNA biotech is offering 11.5 million shares $IONS at...
View ArticleGSK to shut down UK antibiotic facility following end of Sandoz contract
GSK is closing down a facility and is winding down antibiotic manufacturing operations at another factory as Novartis’ Sandoz chooses to end its four-year contract. The British drugmaker will close...
View ArticleClik here to view.
Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up...
A reversible male contraceptive could be a lot closer to reality than you think. Earlier this summer, doctors were tantalized by preliminary data showing that an experimental drug safely reduced sperm...
View ArticleRoche's dual GLP-1/GIP results show promising weight loss, but also high...
Roche’s new weight loss candidate has the efficacy the Swiss pharma was looking for. But it also comes with a high rate of side effects that have plagued the drug category. On Tuesday, the drug...
View ArticleClik here to view.
Lilly's weekly insulin hits primary endpoints in two more late-stage diabetes...
Eli Lilly released two more sets of data for its once-weekly insulin efsitora a week after touting data from another two trials in its late-stage QWINT development program. At the European Association...
View ArticleFDA sends warning letter to Indian drugmaker after finding glass in injections
Indian generic manufacturer Zydus Lifesciences was hit with an FDA warning letter on Tuesday after it shipped vitamin B injections containing glass particles. An inspection from April 15 to April 23 at...
View ArticleCongress spars over whether the Biosecure Act is an overdue crackdown or a...
After the House of Representatives passed a bill to ban biotech and pharma companies from working with a handful of Chinese contractors, opponents of the legislation are raising new questions about the...
View ArticleGilead partners with AI startup Genesis Therapeutics to make small molecule...
A well-funded California biotech startup using AI to design and improve small molecule drug candidates has just struck its third pharma partnership in four years. Gilead announced a new preclinical...
View ArticleOptum's biosimilar business to exclude brand-name Stelara, Humira in 2025
Optum Rx is moving into the biosimilar business with a company it’s calling Nuvaila, and it’s starting out with biosimilars to AbbVie’s blockbuster rheumatoid arthritis drug Humira and J&J’s...
View ArticleAdicet follows other cell therapy biotechs in autoimmune pivot
Adicet Bio is shelving plans to use its lead asset to treat cancer and instead shifting its target to autoimmune diseases. The move, disclosed by the cell therapy-focused biotech in an SEC filing...
View ArticleClik here to view.
BridgeBio ends development of gene therapy for adrenal gland disorder
BridgeBio said Tuesday night it won’t carry forward with a gene therapy for a group of genetic disorders that impair adrenal glands and cause disruptions in producing cortisol. Neil Kumar The...
View ArticleClik here to view.
Sanofi, Regeneron to refile Dupixent for skin condition after new study win
The FDA issued a rare rejection for Sanofi and Regeneron’s Dupixent about a year ago, asking for more efficacy data before it would approve the biologic blockbuster to treat a skin condition marked by...
View ArticleGSK discontinues herpes therapeutic vaccine after Phase 2 disappointment
GSK is ending further development of its therapeutic vaccine for herpes after the candidate failed to prevent recurrent symptom flare-ups in infected adults in a mid-phase trial. The vaccine, known as...
View ArticleRadiant Bio snags $35M for antibody platform, with GSK and Regeneron...
A drug developer aiming to create more potent, effective antibodies unveiled a $35 million Series A on Wednesday with the support of the Bill & Melinda Gates Foundation and Canadian VC firm...
View ArticleClik here to view.
Novo Nordisk's oral amycretin could lead to more weight loss beyond 12 weeks,...
Novo Nordisk touted more data for its oral amycretin, noting that subjects had not reached a plateau in their weight loss at the end of the early-stage trial. The Danish company previously teased...
View Article